ReviewTherapeutic delivery2015
Potent and tumor specific: arming bacteria with therapeutic proteins.
Review in Therapeutic delivery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Antitumor immunotoxin expression is enhanced by Escherichia coli csrB-promoter activity.Oncogene · 2026Article
- Optimization Strategies and Synergistic Applications of EngineeredInternational journal of nanomedicine · 2026Review
- The bidirectional regulatory effects of bacteria on blood vessels in the tumor microenvironment.Discover oncology · 2025Review
- Current status and future perspectives of multi-modal bacteria-based cancer therapies.Clinical and translational medicine · 2025Review
- Enhancing photothermal therapy of tumors with image-guided thermal control of gene-expressing bacteria.Theranostics · 2024Article
- 16S rRNA gene primer choice impacts off-target amplification in human gastrointestinal tract biopsies and microbiome profiling.Scientific reports · 2023Article
- Bacterial delivery of therapeutic proteins to the nuclei of cancer cells.Biotechnology and bioengineering · 2023Article
- Design principles of bioinspired interfaces for biomedical applications in therapeutics and imaging.Frontiers in chemistry · 2022Review
- Effect of Invasion ofAntibiotics (Basel, Switzerland) · 2021Article
- In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy.Scientific reports · 2021Article
- Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model.Oncotarget · 2020Article
- Homologous Quorum Sensing Regulatory Circuit: A Dual-Input Genetic Controller for Modulating Quorum Sensing-Mediated Protein Expression inACS synthetic biology · 2020Article
- Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment.International journal of molecular sciences · 2020Review
- Engineering the gut microbiota to treat chronic diseases.Applied microbiology and biotechnology · 2020Review
- Anticancer Actions of Azurin and Its Derived Peptide p28.The protein journal · 2020Review
- Article
- Targeted Delivery of the Mitochondrial Target Domain of Noxa to Tumor Tissue via Synthetic Secretion System inFrontiers in bioengineering and biotechnology · 2020Article
- Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models.Cancer gene therapy · 2018Article
- Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.Protein science : a publication of the Protein Society · 2017Review
- Advances in bacterial cancer therapies using synthetic biology.Current opinion in systems biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bacteria are perfect vessels for targeted cancer therapy. Conventional chemotherapy is limited by passive diffusion, and systemic administration causes severe side effects. Bacteria can overcome these obstacles by delivering therapeutic proteins specifically to tumors. Bacteria have been modified to produce proteins that directly kill cells, induce apoptosis via signaling pathways, and stimulate the immune system. These three modes of bacterial treatment have all been shown to reduce tumor growth in animal models. Bacteria have also been designed to convert nontoxic prodrugs to active therapeutic compounds. The ease of genetic manipulation enables creation of arrays of bacteria that release many new protein drugs. This versatility will allow targeting of multiple cancer pathways and will establish a platform for individualized cancer medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.